Impact of Platelet Activation in Intracranial Aneurysm Rupture Risk - PLAQRAN

Condition(s) studied

Investigational drug(s) / intervention(s)

Collection of blood sample in aneurysm: In case of an endovascular treatment : * A blood sample (venous or arterial) of 10 ml will be taken at the beginning of the procedure, an intra aneurysmal blood sample (1mL) will be taken during the procedure and a blood sample (arterial) of 1 mL will be taken at the end of the procedure. * Iterative blood samples (arterial) of 10 mL will be taken at each follow up visit. In case of a surgery treatment : * A blood sample (venous or arterial) of 10 ml will be taken at the beginning of the surgery. * A Tissue sample will be taken during the surgery * Iterative blood samples (arterial) of 10 mL will be taken at each follow up visit.

Study summary

Sub arachnoid hemorrhage consecutive to intracranial aneurysm rupture is a devastating disease. Predictors of intracranial aneurysm rupture are limited and focus mainly on size and location. Platelet activation may have a deleterious role on aneurysm rupture. The assumption is that patients with ruptured intracranial aneurysm will present a higher rate of platelet activation compared to patients with non ruptured aneurysms.

Eligibility

Primary outcome measure(s)

• Proportion of patients with platelet activation — in the 7 days before embolisation
  comparison of this proportion between patients with ruptured versus non ruptured intracranial aneurysm

Trial sites (1)

More Fondation Ophtalmologique Adolphe de Rothschild trials in France

Other trials for the same condition